Topical microbicide protects against genital herpes



Scientists at UT Southwestern Medical Center have determined that the immune-system protein interferon plays a key role in “teaching” the immune system how to fight off repeated infections of the same virus. The findings, available online and in the Dec. 15 issue of the Journal of Immunology, have potential application in the development of more

Full Post: Interferon needed for cells to ‘remember’ how to defeat a virus

A topical microbicide that silences two genes can safely protect against genital herpes infection for as long as one week, according to a joint study by researchers at the Albert Einstein College of Medicine of Yeshiva University and Harvard Medical School.

The study, carried out in mice and published today in Cell Host & Microbe , represents a major step toward developing a vaginal microbicide that offers women convenient, long-lasting protection against herpes infection. Such a microbicide might also help in controlling the AIDS epidemic, since the blisters caused by genital herpes make people more susceptible to HIV infection. The study’s principal investigators were Deborah Palliser, Ph.D., assistant professor of microbiology & immunology at Einstein and Judy Lieberman, M.D., Ph.D., professor of pediatrics, Harvard Medical School.

An estimated one in five American adults is infected with herpes simplex virus 2 (HSV-2), which causes the sexually transmitted disease known as genital herpes. Most people don’t realize they’re infected, since symptoms are often mild and can be mistaken for other conditions. When symptoms do occur, they usually appear as blisters on or around the genitals or rectum. When the blisters break, they leave tender sores that usually take two to four weeks to heal. HSV-2 infection is incurable and persists in the body indefinitely, although the number of outbreaks tends to decrease over time.

The most effective way to prevent the transmission of HSV-2 is to avoid sexual contact during an active outbreak and to use condoms for sexual contact between outbreaks. When an outbreak occurs, promptly taking the suppressive antiviral drug valacyclovir can help minimize symptoms and reduce the risk of transmitting the virus.

The microbicide in this study is based on RNA interference (RNAi), a mechanism cells use to protect their genetic machinery from viruses and other threats. RNAi employs short, double-stranded RNAs called small interfering RNAs, or siRNAs. In 2001, scientists discovered that synthetic siRNAs can induce RNA interference in mammalian cells-a finding that has triggered interest in harnessing this strategy for biomedical research and drug development.

The HSV-2 microbicide used in this study inactivates two genes via RNA interference. One siRNA targets a viral gene, thereby silencing virus immediately following application, but suppression lasts for only a couple of days. The second siRNA-specific for a cell-surface protein used by HSV-2 to dock onto cells it infects-takes a few days to silence the gene, but then confers suppression for a week.

By combining the fast-acting-but-short-lived RNAi with the slower-acting-but-long-lived RNAi, the researchers created a vaginal microbicide offering protection that was both immediate (even warding off an HSV-2 “challenge” given shortly before the microbicide was applied) and sustained (protecting against HSV-2 challenge for a week after application).

“A good microbicide for a sexually transmitted disease must offer long-term protection-compliance will be problematic if it has to be applied immediately before sexual intercourse,” says Dr. Palliser. “Our microbicide, with its two siRNAs, provided sustained and uninterrupted protection against HSV-2 infection. And equally important, we achieved these results without causing inflammation of vaginal tissue-a side effect observed with other siRNAs that also risks neutralizing a microbicide’s benefits. We’re hopeful that this experimental microbicide can be turned into a cost-effective therapy for use in developing countries where up to 80 percent of the population is infected with HSV-2.” The researchers are currently working to refine the microbicide and as yet have no plans for clinical trials.

http://www.aecom.yu.edu/

Link




Whether condoms or abstinence, most efforts to prevent sexually transmitted diseases have a common logic: keep the pathogen out of your body altogether. While this approach is certainly reasonable enough, it doesn’t help the countless people worldwide who, for a number of reasons, are not in a position to control their sexual circumstances. Now, Harvard

Full Post: Topical treatment wipes out herpes with RNAi



Researchers at Northwestern University have discovered a critical new way a man can transmit the HIV virus to a woman. Scientists had long believed that the normal lining of the female vaginal tract was an effective barrier to invasion of the HIV virus during sexual intercourse. They thought the large HIV virus couldn’t penetrate the

Full Post: Discovery of new way a man can transmit the HIV virus to a woman



Starpharma Holdings Limited today announced that one of its key patents relating to the use of dendrimers to protect against sexually transmitted infections has been approved in Japan. This approval means that VivaGel and the VivaGel coated condom are now covered by granted patents in all major markets including Europe, the US and Japan. Last

Full Post: Starpharma’s VivaGelR patent approved in Japan



Dysuria is painful urination. It is a condition wherein you experience discomfort, burning sensation, and pain while passing urine. The pain occurs in urethra and perineum (area around the genitals). Dysuria isn’t a disease. It is a symptom of diseases. It prevails in both the sexes but, women experience dysuria more as compared to men. The causes

Full Post: Home Remedies for Dysuria



A new study by researchers at the Bradley Hasbro Children’s Research Center suggests that the incidence of heterosexual anal sex is increasing among teens and young adults - particularly those who have recently had unprotected vaginal sex. These findings mirror recent data that show anal sex rates among adults doubled between the years 1995 and

Full Post: Anal sex being practiced by more teens